

THE ONIVYDE® 1L REGIMEN

NOW APPROVED IN 1L mPDAC



ONIVYDE® pegylated liposomal is indicated in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

In addition, ONIVYDE® is indicated in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas in adult patients who have progressed following gemcitabine-based therapy.

ONIVYDE® was not evaluated for and is not indicated for children who are less than 18 years old.

Above illustration based on Wainberg et al 2023²


Abbreviations: 1L, first-line; mOS, median overall survival; mPDAC, metastatic pancreatic ductal adenocarcinoma; mPFS, median progression-free survival; ONIVYDE® 1L regimen, nanoliposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin; ORR, overall response rate.

1. Prepared in accordance with the approved Malaysian Package Insert dated 06/08/24. 2. Wainberg ZA et al. *Lancet*. 2023;402(10409):1272-1281.

SERVIER
moved by you

SERVIER MALAYSIA SDN BHD
Registration No. 199701036026 - (451526-M)
Unit No. 25-02, Level 25, Imazium, No. 8, Jalan SS21/37,
Damansara Uptown, 47400, Petaling Jaya, Selangor Darul Ehsan
Tel: 603-7726 3866 www.servier.com
25OV15IA For Healthcare Professionals only.

 **onivyde**[®]
pegylated liposomal irinotecan



**ACCESS FULL
PRESCRIBING
INFORMATION BY
SCANNING
THIS QR CODE**